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Abstract
Background Interleukin-8 (IL-8) also referred to as CXCL8, a
memberoftheCXCchemokinefamilythatattractsneutrophils
and other leukocytes, has been associated with cancer.
Angiogenesis is a prime regulator of tumour expansion and
data support that IL-8 is a potent angiogenic factor. Epige-
nomic instability has been postulated to play a role for the
development of multiple neoplasias including colorectal
cancer (CRC). DNA methylation of cytosine residues in CpG
dinucleotides leads to transcriptional silencing of associated
genes.
Method In this study, we comparatively analysed the protein
expressionofIL-8inplasma, tumourand pairednormaltissue
and methylation status of the IL-8 gene to evaluate its impact
on CRC.
Results Collectively, by using Luminex technology, we noted
a significantly higher IL-8 level in cancer tissue compared to
paired normal tissue and that CRC patients exhibit signifi-
cantlyhigherplasmalevelsthanhealthycontrols.Analysedby
methylation-specific polymerase chain reaction, we detected
IL-8 hypomethylation in 64% of the cancerous tissue cases
but no hypomethylation was found in paired normal tissue.
We noted that the CRC patients with IL-8 hypomethylation
revealeda significant higherlevelofIL-8protein incancerous
tissue, which tended to be associated with distant metastasis.
We also observed that patients with distant metastasis showed
a significantly higher plasma level of IL-8 in relation to
patients without distant metastasis.
Conclusion Ourresultssuggestthatthepredominanceofhigh
plasma levels of IL-8 in patients with distant metastasis in
combination with the hypomethylation of the IL-8 promoter
region might be a useful marker of the disease advancement.
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Introduction
Interleukin-8 (IL-8) also referred to as CXCL8, a member of
the CXC chemokine family that attracts neutrophils and other
leukocytes, has been associated with cancer [1–4]. IL-8 is
produced by various cells including macrophages, neutro-
phils, endothelial cells and cancer cells [3, 5]. Several
chemokines promote and regulate neoplastic progression
including metastasis and angiogenesis [6]. IL-8 has been
shown to be expressed higher in colon carcinoma compared
with normal colon tissue [7, 8] and overexpression has also
been noted in colon cancer cell lines [8–11]. Data showed
that overexpression of IL-8 promotes tumour growth and
metastasis and is associated with survival in colon cancer [8,
9]. Moreover, IL-8 acts as an autocrine growth factor for
human colon carcinoma cells [12].
Angiogenesis is a prime regulator of tumour expansion
and in the metastasis of tumour cells. The endogenous
J. Dimberg
Department of Natural Science and Biomedicine,
University College of Health Sciences,
SE-551 11 Jönköping, Sweden
K. Ström: S. Löfgren
Department of Clinical Microbiology, Ryhov County Hospital,
SE-551 85 Jönköping, Sweden
N. Zar:M. Lindh
Department of Surgery, Ryhov County Hospital,
SE-551 85 Jönköping, Sweden
A. Matussek (*)
Department of Laboratory Medicine, Ryhov County Hospital,
SE-551 85 Jönköping, Sweden
e-mail: andreas.matussek@lj.se
Int J Colorectal Dis (2012) 27:709–714
DOI 10.1007/s00384-011-1367-5proangiogenic factor, vascular endothelial growth factor
(VEGF), is a major regulator of both normal and pathological
neovascularization and is upregulated in colorectal cancer
(CRC) [13, 14]. Additionally, VEGF correlates with inva-
siveness, metastasis and prognosis [13, 14]. Besides VEGF,
IL-8 is also a very potent angiogenic factor [3, 6] and data
support the existence of a pathway by which IL-8 controls
the expression of VEGF in endothelial cells [15].
Several investigations have indicated that matrix metal-
loproteinases (MMPs) have fundamental roles in pathological
processes in cancer by degradation of the basal membranes
and extracellular matrix [16]. Moreover, reduced MMP-9
expression is associated with a longer survival rate in CRC
patients [17]. Interestingly, it has been observed that IL-8 can
enhance the production of MMPs in ulcerative colitis and
melanoma cells [18, 19].
Epigenetic modifications of DNA have been postulated to
play a role in the development of multiple neoplasias
including CRC [20, 21]. DNA methylation of cytosine
residues in CpG dinucleotides leads to transcriptional
silencing of associated genes. Promoters with methylated
CpG units, which have their transcriptional activity lowered,
may function as an alternative mechanism of repressing
tumour suppressor genes. The aberrant methylation of gene
promoter regions is widely studied and this epigenetic event
in human malignancies may affect the cell cycle control and
differentiation [20–22].
The human IL-8 gene is located on chromosome 4 and
consists of four exons [23]. It has been reported that the
expression of IL-8 can be modulated by the methylation of
its promoter and that atypical methylation pattern correlates
strongly with the metastatic potential of breast carcinoma
cells [24]. Moreover, studies have proved hypomethylation
of the IL-8 gene promoter in oral epithelial cells in
aggressive and chronic periodontitis [25, 26].
Data concerning the methylation status in the gene
promoter of IL-8 in human CRC is limited. Therefore, we
determined the methylation status in cancerous and paired
normal tissue to evaluate its value in CRC and the association
to the IL-8 protein expression in CRC patients and clinical
factors.
Materials and methods
Patients and tissue sampling
The subjects of this study were 50 CRC patients from
southeastern Sweden and informed consent was obtained
from each subject. The study was approved by the Local
Ethics Committee of Linköping University, Sweden.
Tissuesampleswerecollectedwhenthepatientsunderwent
surgical resections for primary colorectal adenocarcinomas at
the Department of Surgery, Ryhov County Hospital, Jönköping,
Sweden. Clinicopathological characteristics from the patients
were received from surgical and pathological records. Tumour
tissue and adjacent normal mucosa (about 5 cm from the
tumour) from each patient were excised and immediately frozen
at −70°C until analysis.
The patient group represented 28 males and 22 females
withameanageof69years(range,36–90).Thetumourswere
located in the colon (n=29) and rectum (n=21) and were
classified according to the American Joint Committee on
Cancer classification system: stage I (n=3), stage II (n=20),
stage III (n=14) and stage IV (n=13). Histological grading
was well differentiated in 7 patients, moderately differentiated
in 29 patients and poorly differentiated in 14 patients.
Cell lines
TwoestablishedhumancoloncancercelllinesCaco-2andHT-
29 were purchased from American Type Culture Collection
(Rockville,MD,USA).Thecelllinesweregrownaccordingto
the supplier's instructions and the growth media were
Essential Medium (Caco-2) and Mc Coy 5a (HT-29).
Lysates and plasma samples
Tumour tissue and paired normal mucosa as well as cell
lines were homogenised in ice-cold lysis buffer containing
PBS (9.1 mM dibasic sodium phosphate, 1.7 mM mono-
basic sodium phosphate, 150 mM NaCl, pH=7.4) and 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulphate, 100 μg/ml phenylmethylsulphonyl fluo-
ride, 2 μg/ml aprotinin, 1 mM sodium orthovanadate and
1 μg/ml leupeptin. The lysate was placed on ice for 30 min
and then centrifuged at 13,000g for 10 min. Protein content
of the supernatant fluid was determined for each sample
using the Bradford protein assay (Bio-Rad Laboratories,
CA, USA).
Forty-nine of the CRC patients were available for plasma
samplescollectionbeforesurgery.Blooddonors(n=51),from
Ryhov County Hospital, with no known CRC history came
from the same geographical region as the CRC patients and
were selected as controls. This control group consisted of 28
males and 23 females with a mean age of 65 years (range,
46–71). All blood samples were centrifuged and the
separated plasma was stored at −70°C.
Quantification of IL-8 in tissue, cell lines and plasma
IL-8 was measured in tissue, cell lines and plasma using a
Luminex bead-based technology (Bio-Rad, Hercules, CA,
USA).ThetissueandcelllinelevelsofIL-8wereexpressedas
picogrammes per milligramme of protein. IL-8 in the plasma
was expressed as picogrammes per millilitre.
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DNA was isolated from tissue samples and cell lines using
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Purified
DNA (0.5 μg) was treated with bisulphite and purified using
the EZ DNA methylation-gold kit (Zymo Research, Irvine,
CA, USA) according to the manufacturer's instructions.
Methylation-specific polymerase chain reaction
Methylation-specific polymerase chain reaction (MSP) was
performed in principal as previously been described [25, 27].
The primer sequences were based on a previous report [25]
and were forward: 5′-AAAATTTTCGTTATATTTCG-3′ and
reverse: 5′-TCCGATAACTTTTTATATCAT-3′ for the methyl-
ated reaction and forward: 5′-AAAATTTTTGTTATATTTTG-
3′ and reverse: 5′-TCCAATAACTTTTTATATCAT-3′ for the
unmethylated reaction. The primers were synthesised commer-
cially (TIB Molbiol, Berlin, Germany). The methylated and
unmethylated MSP conditions were as follows: initial cycle at
95°C for 5 min followed by 30 cycles at 95°C for 45 s; 47°C
for 45 s; 72°C for 45 s and final elongation at 72°C for 7 min.
The amplification product (173 bp) was visualised by UV
illumination on 3% agarose gel containing Gel Red (Biotium,
CA, USA). The total volume of the PCR mixture was 25 μl
and contained 60 ng bisulphite-modified DNA, 0.5 μMo f
each primer (TIB Molbiol), 1.5 mM MgCl2, 200 μMo fe a c h
deoxynucleotide triphosphate, 2.5 U Taq DNA polymerase and
reaction buffer 20 mM Tris–HCl (pH 8.3), 20 mM KCl and
5m M( N H 4)2SO4 (Fermentas, Burlington, Canada).
Statistical analysis
Chi-square test was used to investigate the difference in the
methylation status in the groups. Differences of IL-8 levels
between tumour and paired normal tissues were examined
by the Wilcoxon signed rank test. Differences of IL-8 in
plasma between CRC patients and controls were tested by
the Mann–Whitney U test. Differences between IL-8 levels
in cell lines were tested using Student's t test and the data
were expressed as mean values±SEM. Statistical analyses
were performed using SPSS for Windows computer
package (Rel. 14.0, SPSS Inc., Chicago: 2005, USA).
Results were considered significant at P<0.05.
Results
IL-8 promoter methylation in CRC tissues and paired
normal tissues
Representative band profiles of the MSP reactions of the IL-
8 promoter region are illustrated in Fig. 1. The unmethylated
(U) signals were detected in all colorectal samples and in
both cell lines. In the paired normal tissue, methylated (M)
signals were detected in all cases of the patients (50/50) and
in Caco2 cells. In the cancer tissue, we observed that 36%
(18/50) of the cases were methylated and that HT-29 cells
showed hypomethylation status. The difference in methyla-
tion frequency between cancerous tissue and paired normal
tissue was statistically significant (P<0.05) (Fig. 2). When
subdividing the patients in groups of no distant metastasis
(stage I–III) (n=37) and distant metastasis (stage IV), the
stage IV patients (n=13) revealed 15.3% (2/13) methylated
signals in cancer tissue which tended to be a lower frequency
(P=0.07) compared to stage I–III 43.2% (16/37) (data not
shown). There was no statistically significant association
between MSP findings with other clinical parameters such as
gender, location or histological grading (data not shown).
Levels of IL-8 protein in colorectal tissue, plasma and cell
lines
Using Luminex bead-based technology, we investigated the
concentrations of IL-8 protein in lysates of CRC tissue and
paired normal tissue and in plasma from 49 patients and 51
healthy controls. The CRC tissue levels of IL-8 (median,
419 pg/mg; range, 25–7,568) showed significant differences
(P<0.001) in comparison with normal tissue (median,
77 pg/mg; range, 3–2,760) (Fig. 3). Evaluation of the
relative expression (tumour vs. normal tissue) showed 94%
(47/50) upregulation for IL-8.
Whenassessingthe cancer tissuelevels of IL-8 in detail, we
observed thatthepatientswitha hypomethylated status(n=32)
(median, 473 pg/mg; range, 60–7,568) showed significantly
Fig. 1 Representative results of MSP analysis of the IL-8 gene in two
CRC patients and two cell lines. The PCR products (173 bp) in the
lanes M and U indicate the presence of methylated and unmethylated
fragments, respectively. T tumour and N normal paired tissue
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Fig. 2 Methylation (M) frequency of the IL-8 gene promoter between
tumour and normal tissue was statistically significant, *P<0.05.
Unmethylated status (U) was detected in all specimens
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(median, 320 pg/mg; range, 25–1,290) which displayed
promoter methylation (Fig. 3). Furthermore, we found
that the IL-8 concentration in plasma from CRC patients
(median, 18.7 pg/ml; range, 1.9–68.2 pg/ml) differed signif-
icantly from the healthy controls (median, 7.12 pg/ml; range,
3.4–24.6 pg/ml), P<0.001 (Fig. 4).
T h el e v e l so fI L - 8i na l lt h ea n a l y s e dt i s s u ea n dp l a s m a
samples from the CRC patients did not correlate with any
clinical characteristics such as age, gender, histological
grading, location and stage apart from the fact that the patients
with distantmetastasis showeda significantly(P<0.01) higher
plasma level (median, 31.7 pg/ml; range, 9.6–68.2 pg/ml) in
comparison with patients without distant metastasis (median,
14.4 pg/ml; range, 1.9–62.7 pg/ml) (Fig. 4). In the human
colon adenocarcinoma cell lines, we noted in three experi-
ments that the protein level of IL-8 was 17.7±3.6 and 3.3±
1.4 pg/mg in HT-29 and Caco2, respectively. The difference
of IL-8 concentrations between HT-29 and Caco2 was
statistically significant at the 0.05 level.
Discussion
IL-8 is a proinflammatory cytokine and chemoattractant
factor for leukocytes and is involved in tumour growth,
metastasis and survival in colon cancer [6, 8, 9]. Moreover,
IL-8 is a very potent angiogenic factor [3, 6].
Epigenomic instability has been postulated to play a role
for the development of multiple neoplasias including CRC
[20, 21]. Methylation of gene promoter regions is widely
studied, and this epigenetic event affect the cell cycle
control and differentiation in human malignancies. Studies
have described that aberrant hypermethylation of promoter
CpG islands is linked to gene silencing and loss of tumour
suppressor function [20–22].
Recently, a marked hypomethylated status of the IL-8 gene
promoter in aggressive periodontitis, which may have
relevance for the inflammatory reactions, has been shown
[25]. The protein expression profile of IL-8 in relation to
methylation of the IL-8 gene promoter in human CRC has
not been studied.
In agreement with previous observations, we found that
CRC patients have a significantly higher level of IL-8 protein
incancertissueincomparisonwithpairednormaltissue[7, 8].
Analysed by MSP, we detected IL-8 hypomethylation in
64% of the cancer tissue cases but no hypomethylation was
found in paired normal tissues. Furthermore, we noted that
the CRC patients with IL-8 hypomethylation revealed
significantly higher levels of IL-8 protein in cancer tissue.
Associations between tissue IL-8 level or methylation status
and a series of clinical characteristics were not found.
However, our results indicate that patients with distant
metastasis tend to show lower methylation frequency (P=
0.07) in cancer tissue compared with patients without distant
metastasis. According to previous reports, we observed a
higher constitutive level of IL-8 protein in the colon cancer
cell line HT-29 compared to Caco2 [8–11]. This observation
can be explained by the hypomethylation status we found in
HT-29 and is in line with the higher levels of IL-8 protein in
cancer tissue with hypomethylation status.
A possible explanation for the observed higher expression
of IL-8 in cancerous compared with normal tissue is that the
expression may be controlled by specific transcription factors.
The evaluated CpG dinucleotides in this study, which
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Fig. 4 Box plot illustration of the protein levels of IL-8 in plasma
from 49 CRC patients and 51 healthy controls. The plasma
concentrations of IL-8 in CRC patients were higher compared to
controls and revealed higher levels in patients with distant metastasis
(stage IV) than in those without distant metastasis (stage I–III).
Medians are shown by horizontal bars
P<0.001
8000
P<0.05
6000
7000
5000
6000
3000
4000
2000
3000
1000
T
i
s
s
u
e
 
I
L
8
 
(
p
g
/
m
g
 
p
t
o
t
e
i
n
)
0
T N T(U) T(M)
(n=50) (n=50) (n=32) (n=18)
Fig. 3 Box plot illustration of the protein levels of IL-8 in colorectal
tissue from 50 CRC patients. The levels of IL-8 in tumour tissue (T)
were higher compared to normal (N) paired tissue. The IL-8 levels are
higher in tumour tissue with only unmethylated (U) signals analysed
by MSP in relation to tumour tissue with methylated (M) signals.
Medians are shown by horizontal bars
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transcriptionalrepression, are located withinnucleotides −136
and +43 in the IL-8 gene promoter [25]. This region has been
shown to contain the binding sites for the transcription
factors activator protein-1 and nuclear factor-ĸB which are
responsible for the constitutive expression of the IL-8 gene
[3]. These factors are enhanced in CRC and have a role in
the colorectal carcinogenesis [28].
OurstudyshowedsignificantlyhigherIL-8levelsincancer
tissue compared with normal tissue, both overall and
particularly in patients with IL-8-hypomethylated gene in
cancer tissue. Methylation of the IL-8 promoter region may
play a pivotal role to modulate the transcriptional activity and
is related to overtranscription.
The functional consequence of the IL-8 gene promoter
methylation in human CRC is not established. Our results
suggest that the hypomethylation of the IL-8 promoter region
could have a complementary driving force for the develop-
ment of CRC by modulating the cancer tissue IL-8 level. In
this study we noted that CRC patients exhibit significantly
higher plasma levels of IL-8 in relation to healthy controls,
which is in agreement with previous reports [10, 29].
Moreover, the patients with distant metastasis showed
significantly higher plasma levels than in patients with no
distant metastasis. These findings are in line with the study
by Ueda et al. [29] showing that circulating levels of IL-
8 were significantly higher in patients with metastasis than in
patients without metastasis.
Taken together, our study suggest that hypomethylation
of the IL-8 promoter region may play a part as a
prognostic factor in CRC. The predominance of high
plasma levels of IL-8 in patients with distant metastasis
in combinationwiththehypomethylationoftheIL-8promoter
region might be a useful indicator of advanced CRC. We are
aware that our finding needs to be confirmed by extended
studies before drawing a final conclusion regarding these
suggestions.
The data presented in this report are prerequisite to a
forthcoming study of CRC patients to evaluate the influence
ofIL-8 protein expression and IL-8 gene methylation statusin
cancer and normal tissue on a 5-year survival and recurrence
rate. Moreover, the clinical significance of free-circulating
tumour-associated DNA in CRC patients will be evaluated
regarding DNA methylation status of the IL-8 gene promoter.
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